Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

By afschroeder • May 17, 2026

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb). 2026 May 16. doi: 10.1007/s13555-026-01738-6. Epub ahead of print. PMID: 42143206.

Tags: Dermatology, DLQI, Oral therapy, PASI, patient-reported outcomes, plaque psoriasis, psoriasis, Publications, Skin clearance, TYK2 inhibitor, Zasocitinib

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani[...]

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study

Chen A, Krenitsky A, Perry SS, Tan KW, Swick BL, Anderson KR, Barry KK, Kelsey B, Carlberg VM, Coughlin CC, Craddock M, Fadzeyeva H, Ferringer[...]

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52[...]